Photoprotection : Part II. Sunscreen: Development, efficacy, and controversies - 14/11/13

Doi : 10.1016/j.jaad.2013.08.022

Rebecca Jansen, MD ^a, Uli Osterwalder, MS ^b, Steven Q. Wang, MD ^c, Mark Burnett, MD ^c, Henry W. Lim, MD ^a,^⁎
^a Department of Dermatology, Henry Ford Hospital, Detroit, Michigan
^b BASF Personal Care and Nutrition GmbH, Monheim, Germany
^c Division of Dermatology, Memorial Sloan Kettering Cancer Center, New York, New York

^∗Reprint requests: Henry W. Lim, MD, Department of Dermatology, Henry Ford Medical Center – New Center One, 3031 W Grand Blvd, Ste 800, Detroit, MI 48202.

Abstract

In addition to the naturally occurring, physical, and systemic photoprotective agents reviewed in part I, topical ultraviolet radiation filters are an important cornerstone of photoprotection. Sunscreen development, efficacy, testing, and controversies are reviewed in part II of this continuing medical education article.

Le texte complet de cet article est disponible en PDF.

Key words : oxybenzone, photoprotection, photostability, Sun Protection Factor, sunscreen, sunscreen controversies, ultraviolet filter

Abbreviations used : AAP, AO, AVO, BEMT, CW, E1,1, EU, FDA, ISO, MED, PPD, ROS, SPF, TiO₂, UK, USAN, UV, UVA, UVB, UVR, ZnO

Plan

Sunscreens: Topical photoprotective agents

The notion of the “ideal sunscreen”

Ultraviolet filters

Sunscreen use

Evaluation of efficacy

Factors affecting sunscreen efficacy

Initiatives to enhance clarity and consistency of sunscreen use

Sunscreen controversies

Oxybenzone

Retinyl palmitate

Ultraviolet filters and inflammation

Nanoparticles

Antioxidants

Vitamin D synthesis

Use in pediatric populations

	Funding sources: None.
	Dr Lim has served as consultant for Ferndale, La Roche-Posay, Pierre Fabre, Uriage, and Palatin. He has received research grants from Clinuvel and Estee Lauder. Mr Osterwalder is a full time employee of BASF. Dr Wang has served on the advisory board of L'Oreal. Drs Burnett and Jansen have no conflicts of interest to declare.